利用递送自组装纳米颗粒的重组流感病毒进行抗SARS-CoV-2黏膜疫苗接种
本研究利用反向遗传学构建携带SARS-CoV-2受体结合域(RBD)基因的重组流感病毒,分别以单体、三聚体或铁蛋白纳米颗粒形式呈现RBD。小鼠鼻内免疫后,铁蛋白纳米颗粒组血清抗RBD应答优于单体或三聚体组;黏膜免疫诱导呼吸道IgA、RBD特异性肺驻留记忆B细胞和生发中心(GC)B细胞。既往肌肉注射疫苗的动物经鼻内加强后,黏膜IgG、IgA、GC和记忆B细胞及肺部中和滴度均增强。
要点
- 重组流感病毒载体鼻内免疫可诱导小鼠血清抗RBD抗体及呼吸道黏膜免疫应答。
- 铁蛋白纳米颗粒形式的RBD所诱导的血清学抗RBD应答优于单体或三聚体形式。
- 既往肌肉注射疫苗后鼻内加强可增强黏膜抗体、B细胞应答及肺部SARS-CoV-2中和滴度。
核心结论
- 基于重组流感病毒的疫苗能有效递送高免疫原性自组装纳米颗粒,在呼吸道黏膜产生抗体和B细胞。
研究设计与样本
- 利用反向遗传学构建携带SARS-CoV-2 RBD基因(单体、三聚体或铁蛋白纳米颗粒形式)的复制 competent 重组流感病毒,并在小鼠中进行鼻内免疫及既往肌肉注射后的鼻内加强评估。
主要发现
- 小鼠鼻内免疫后产生强血清学抗RBD应答,铁蛋白纳米颗粒超过单体或三聚体RBD应答。
- 黏膜免疫诱导呼吸道IgA、RBD特异性肺驻留记忆B细胞和生发中心B细胞,而胃肠外和黏膜免疫均诱导血清抗RBD IgG。
- 既往肌肉注射疫苗的动物经鼻内加强后,黏膜IgG、IgA、生发中心B细胞和记忆B细胞及SARS-CoV-2肺部中和滴度均增强。
- 肺部抗原再暴露召回RBD特异性记忆B细胞,增加肺引流淋巴结中抗体分泌细胞,并维持肺部生发中心B细胞。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recombinant influenza viruses are promising vectors that can bolster antibody and resident lymphocyte responses within mucosal sites. This study evaluates recombinant influenza viruses with SARS-CoV-2 RBD genes in eliciting mucosal and systemic responses. Using reverse genetics, we generated replication-competent recombinant influenza viruses carrying heterologous RBD genes in monomeric, trimeric, or ferritin-based nanoparticle forms. Following intranasal immunisation, mice developed potent serological anti-RBD responses, with ferritin nanoparticles superseding monomeric or trimeric RBD responses. While parenteral and mucosal immunisation elicited robust anti-RBD IgG in serum, mucosal immunisation seeded respiratory IgA, RBD-specific lung-resident memory and germinal centre (GC) B cells. In animals with prior intramuscular vaccination, intranasal boosting with recombinant influenza vectors augmented mucosal IgG, IgA, GC and memory B cells, and SARS-CoV-2 lung neutralising titres. Recall of RBD-specific memory B cells via antigen re-exposure in the lung increased antibody-secreting cells in the lung-draining lymph nodes, with maintenance of lung GC B cells. Recombinant influenza-based vaccines effectively deliver highly immunogenic self-assembling nanoparticles, generating antibodies and B cells in the respiratory mucosa. This strategy provides a tractable pathway to augment lung-localised responses against recurrent respiratory viral infections.
引用
- Pilapitiya D, Lee WS, Vu MN, et al. Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses delivering self-assembling nanoparticles. Vaccine. 2024. PMID: 39740385. doi:10.1016/j.vaccine.2024.126668
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。